Developer docs
API playgroundTry for free, no card

Search company profiles

TAE Life Sciences

Full company profile

uuid00009np

Namestring
TAE Life Sciences
Legal namestring
TAE Life Sciences US, LLC
Company typeenum
Private
Founded yearint
2017
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
boron neutron capture therapy, radiation oncology systems, accelerator neutron sources, boron-10 drug development, targeted cancer radiotherapy
Industry3 codes
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYEUAKAIAD
Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
NAICS code3 codes
  • Irradiation Apparatus Manufacturing334517
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • X-Ray Apparatus & Tubes & Related Irradiation Apparatus3844
Product category
Radiation Oncology Systems
Social media profiles2 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Alphabeam BNCT System Sales
TypeHardware Sales
Description

Sale of the Alphabeam accelerator-based neutron beam system to hospitals and cancer treatment centers for installation in clinical facilities. The system is designed for single or multi-room facility deployment.

taelifesciences.com
2Boron-10 Drug Products
TypeOne Time License
Description

Proprietary boron-10 targeting drugs including BPA, TC220, and other novel compounds for use in BNCT treatment protocols. Partnership with Biddle Sawyer and Kinentia Biosciences for manufacturing.

taelifesciences.com
3Distribution Partnerships
TypeLicensing Royalties
Description

Revenue generated through exclusive distribution agreements with regional partners across multiple territories including Southeast Asia, Australia/New Zealand, Turkiye/Eastern Europe/Central Asia, and India.

taelifesciences.com
4BPA (Steboronine) Commercialization
TypeLicensing Royalties
Description

Exclusive commercial partnership with Stella Pharma for BPA development and commercialization in USA and European markets. Stella Pharma's BPA (Steboronine) is the world's first and only clinically approved boron drug for BNCT.

taelifesciences.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Contact sales for BNCT system and drug pricing
ModelOtherBilling cadenceMulti-year contract
Notes

TAE Life Sciences does not publicly disclose pricing. Direct inquiry required for Alphabeam BNCT system and boron drug candidates.

taelifesciences.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Alphabeam
Description

The Alphabeam™ Neutron System is the company's accelerator-based neutron source designed for hospital installation, producing low-energy neutrons for BNCT treatment.

taelifesciences.com
+4 more records
Core offering1 text field

TAE Life Sciences develops Boron Neutron Capture Therapy (BNCT) technology, combining proprietary boron-10 targeted drugs with the Alphabeam™ accelerator-based neutron beam system for biologically targeted radiation therapy of cancer. The Alphabeam system is a compact tandem accelerator-based neutron source designed for hospital installation, while the boron-10 drug pipeline includes BPA, TC220, TC221, TC440, BTS, Antibody Boron Conjugates, and biodegradable nanoparticles targeting recurrent, invasive, and treatment-resistant cancers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 3x more destructive to cancer cells than standard radiotherapy
+7 more records
Product overview1 text field

TAE Life Sciences is developing a comprehensive BNCT (Boron Neutron Capture Therapy) platform consisting of the Alphabeam™ Neutron System (an accelerator-based neutron source for hospital deployment) combined with a pipeline of proprietary boron-10 drugs (including BPA, TC220, TC221, TC440, BTS, Antibody Boron Conjugates, and biodegradable nanoparticles). The Alphabeam system generates low-energy neutrons that interact with boron-10 drugs accumulated in tumor cells, causing selective destruction of cancer cells while sparing healthy tissue. The company is the only organization developing both the neutron beam system and targeted boron drugs internally for BNCT.

Product and service8 records
1Alphabeam Neutron System
CategoryMedical Device - Radiation Therapy
Description

A compact tandem accelerator-based neutron source designed for hospital installation that generates low-energy neutrons for BNCT cancer treatment. Features 2.5 MeV proton energy, 10+ mA beam current capacity, lithium neutron target technology, negative ion electrostatic accelerator with no moving parts, and the smallest facility footprint for in-hospital use. Targets hospitals and cancer treatment centers implementing biologically targeted radiation therapy for recurrent, invasive, and treatment-resistant cancers.

2BPA (Boronophenylalanine) / Steboronine
CategoryPharmaceutical - Boron Drug
Description

The first clinically approved boron-10 drug for BNCT, approved in Japan for head and neck cancer treatment. TAE Life Sciences is the exclusive commercial partner for Stella Pharma's BPA in the USA and Europe, working toward FDA and European approval under the product name Steboronine.

3TC220 (Boronated Amino Acid Analog)
CategoryPharmaceutical - Boron Drug
Description

A novel boronated amino acid analog drug for BNCT targeting tumors expressing LAT-1, demonstrating superior boron delivery compared to BPA in preclinical studies. In preclinical development for GBM, breast, head and neck, and melanoma cancers. Manufactured by Biddle Sawyer with Kinentia Biosciences as exclusive manufacturer for US market.

4TC221
CategoryPharmaceutical - Boron Drug
Description

A next-generation boron drug candidate in preclinical development targeting lung, colon, and skin cancers.

5TC440 Boronated Dipeptide
CategoryPharmaceutical - Boron Drug
Description

A boronated dipeptide compound demonstrating 2-3x higher boron delivery than BPA in xenograft models with 41% complete tumor remission versus 20% for BPA at same dose. Formulated in aqueous solutions at concentrations greater than 150mg/ml, with dual uptake via PEPT1 and LAT1 transporters.

6BTS (Boronotyrosine) / BTS(OMe)
CategoryPharmaceutical - Boron Drug
Description

A patented borylated amino acid composition (US Patent No. 11,884,688 B2) comprising tyrosine derivatives BTS and BTS(OMe) for use in BNCT. Demonstrated 2-4x higher cellular uptake compared to BPA, 60% boron retention after 18 hours versus less than 20% for BPA, and improved tumor-to-blood ratio of 28:1 versus 6:1 for BPA.

7Antibody Boron Conjugates (ABCs)
CategoryPharmaceutical - Boron Drug
Description

Next-generation boron drugs leveraging antibody-drug conjugate technology to improve tumor targeting and increase boron loading per cell. TAE Life Sciences has developed boron-enriched linkers (BELs) capable of carrying up to 400 boron atoms per antibody.

8Biodegradable Nanoparticles (BPMOs)
CategoryPharmaceutical - Boron Drug
Description

Biodegradable mesoporous organosilica nanoparticles (BPMOs) developed in collaboration with Kyoto University for enhanced boron-10 delivery using the EPR effect for tumor targeting.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-20
Description

Research and clinical collaboration for implementation of BNCT system in Italy. CNAO is one of few facilities worldwide capable of delivering hadrontherapy using both protons and carbon ions, having treated over 6,000 patients. Expanding with BNCT including helium therapy, upright positioning systems, and BNCT system from TAE Life Science.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-05
Description

Exclusive distribution agreement for Turkiye, Eastern Europe, and Central Asia. Bozlu Holding is a diversified holding company headquartered in Istanbul with over 35 years of healthcare services expertise. Responsible for marketing, promoting, distributing, and selling the Alphabeam BNCT system and supporting deployment at initial clinical sites for regulatory approval in the region.

3Institut du Cancer de Montpellier (ICM)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-12-18
Description

Launch of AMBER Project to establish BNCT in France. Project aims to deploy TAE Life Sciences' Alphabeam BNCT system contingent on securing 45 million euros in funding to build dedicated facility.

biospace.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-25
Description

MOU signed to be the first US site to install the Alphabeam BNCT system and execute first US clinical trials. Focus on head and neck and brain cancers.

5Transmedic Group
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-23
Description

Strategic partnership to bring BNCT to Southeast Asia. Transmedic, a leading medical technology distributor headquartered in Singapore with over 40 years of local expertise, represents TAE Life Sciences in key Southeast Asian markets including Singapore, Malaysia, Hong Kong, and Thailand. Provides clinical, operational, and regulatory support to bring Alphabeam BNCT to regional hospitals.

taelifesciences.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-01
Description

Distribution agreement for Australia and New Zealand. alphaXRT, the leading independent supplier of radiation oncology equipment in Australia and New Zealand since 1990, will distribute Alphabeam BNCT system and novel boron drugs while also providing associated services. alphaXRT holds the regulatory certificate for BNCT in the region.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-15
Description

Preclinical research collaboration demonstrating breakthrough results in BNCT. Utilizing TAE Life Sciences' novel boron-10 drugs and Kyoto University Research Reactor (KURR) neutron source, research published in Journal of Medicinal Chemistry demonstrated abscopal effects and immune memory responses in BNCT treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-13
Description

Strategic collaboration for BPA development, commercialization, and expansion in USA and European markets. Stella Pharma's BPA (Steboronine) is the world's first and only clinically approved boron drug for BNCT. Japan approved BNCT with Stella Pharma's BPA for head and neck cancers. TAE Life Sciences serves as exclusive commercial partner for Stella Pharma's BPA in USA and Europe. Clinical trials anticipated to begin in 2026.

9Radiosurgery Global
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-06-05
Description

New distribution partner for India. RSG provides comprehensive support through network of consultants and advisors specializing in sales channels, project management, construction, digital and print marketing, investment advisory, engineering, service, and financing.

taelifesciences.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-04
Description

Partnership for Chinese market where TAE Life Sciences' neutron beam system is a key component of Neuboron's NeuPex AB-BNCT System. System received performance acceptance and passed Class III registration inspection enabling human BNCT clinical trials to begin in China. First US company to achieve such recognition. Clinical trials commenced at Xiamen Humanity Hospital.

11Franciszek Lukasczyk Oncology Center (FLOC)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-06-28
Description

Partnership with leading cancer center in Poland for new state-of-the-art BNCT facility. Construction projected to complete by 2025 with first clinical trials scheduled to commence in spring 2026.

taelifesciences.com
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-04-15
Description

Exclusive agreement with Biddle Sawyer as supplier of TC220, a novel boronated amino acid analog drug for BNCT. Biddle Sawyer enlisted Kinentia Biosciences as exclusive manufacturer of TC220 for US market to refine and streamline drug's manufacturing process in GMP facility.

13Xiamen Humanity Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-15
Description

First accelerator-based BNCT clinical research center in China using TAE Life Sciences' Neutron Beam System as part of Neuboron Medical Group's NeuPex System. First cancer patient treatments completed.

taelifesciences.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-30
Description

Strategic partnership to address unmet need in glioblastoma treatment, combining Aivita's stem cell applications with TAE Life Sciences' BNCT technology.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-12-30
Description

Partnership to bring TAE Life Sciences' targeted radiation therapy to South Korea for treatment of difficult-to-treat cancers such as brain, head and neck cancers and melanoma.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-10-27
Description

Agreement to provide Alphabeam Neutron System for treatment of invasive, recurrent and difficult to treat cancers in Italy.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

China-based developer of the NeuPex AB-BNCT system that integrates TAE Life Sciences' neutron beam with Neuboron technology. Direct competitor in BNCT platform delivery and the closest peer in accelerator-based BNCT system development.

TypeDirect peer
Description

Japanese pharmaceutical company that developed Steboronine (BPA), the world's first clinically approved boron drug for BNCT, approved in Japan for head and neck cancer. Direct peer in BNCT drug development and TAE's exclusive US/EU commercial partner.

TypeDirect peer
Description

Japanese industrial conglomerate that developed reactor-based BNCT systems (used at Kyoto University and other Japanese centers). Direct competitor in BNCT hardware, particularly for hospital and research installations in Asia.

TypeBroad incumbent
Description

US-based radiation oncology systems company (CyberKnife, TomoTherapy) where TAE's CEO Robert Hill was previously SVP. Competes for the same hospital radiation oncology capital budgets but with established photon-based alternatives rather than BNCT.

TypeBroad incumbent
Description

Swedish developer of RayStation treatment planning software, which is integrated with TAE's Alphabeam system. Competes in radiation oncology treatment planning broadly and is a strategic partner/dependency for TAE's BNCT workflow.

TypeBroad incumbent
Description

Global leader in radiation oncology hardware and software (TrueBeam, Ethos), now part of Siemens Healthineers. Competes for hospital oncology capex with mature conventional and adaptive radiotherapy platforms that BNCT must displace.

TypeBroad incumbent
Description

Swedish-Swiss manufacturer of linear accelerators and radiation therapy solutions including the Elekta Unity MR-LinAc. Competes in the same hospital radiation oncology purchasing decisions where TAE's BNCT system would be evaluated.

8Ion Beam Applications (IBA)
TypeBroad incumbent
Description

Belgian leader in proton therapy systems (ProteusONE, ProteusPLUS) and a major competitor for the particle therapy capital budgets that BNCT systems must compete against in leading cancer centers.

TypeEmerging player
Description

US-based developer of compact proton therapy systems (MEVION S250i). Competes with TAE in the niche of smaller-form-factor hospital-installable particle therapy, pursuing similar miniaturization thesis.

TypeBroad incumbent
Description

Japanese conglomerate with significant proton and particle therapy system business globally. Competes for hospital particle therapy installations and represents an alternative path for hospitals exploring advanced radiotherapy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TAE Life Sciences

Radiation Oncology Systemstaelifesciences.com

TAE Life Sciences firmographics

Firmographics
Name
TAE Life Sciences
Legal name
TAE Life Sciences US, LLC
Website
https://taelifesciences.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

TAE Life Sciences industry classification

Industry
Product category
Radiation Oncology Systems
NAICS
Irradiation Apparatus Manufacturing (334517), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)
akta.pro industry
PRIMARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYEUAKAIAD
Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)

Keywords

  • Boron neutron capture therapy
  • Radiation oncology systems
  • Accelerator neutron sources
  • Boron-10 drug development
  • Targeted cancer radiotherapy

Where TAE Life Sciences is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Offices3 records

Markets served

TAE Life Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Alphabeam BNCT System Sales: Sale of the Alphabeam accelerator-based neutron beam system to hospitals and cancer treatment centers for installation in clinical facilities. The system is designed for single or multi-room facility deployment.
  2. Boron-10 Drug Products: Proprietary boron-10 targeting drugs including BPA, TC220, and other novel compounds for use in BNCT treatment protocols. Partnership with Biddle Sawyer and Kinentia Biosciences for manufacturing.
  3. Distribution Partnerships: Revenue generated through exclusive distribution agreements with regional partners across multiple territories including Southeast Asia, Australia/New Zealand, Turkiye/Eastern Europe/Central Asia, and India.
  4. BPA (Steboronine) Commercialization: Exclusive commercial partnership with Stella Pharma for BPA development and commercialization in USA and European markets. Stella Pharma's BPA (Steboronine) is the world's first and only clinically approved boron drug for BNCT.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractContact sales for BNCT system and drug pricing

Go-to-market motion4 records

Distribution channels6 records

Marketing channels7 records

TAE Life Sciences product offering

Product offering

Core offering

TAE Life Sciences develops Boron Neutron Capture Therapy (BNCT) technology, combining proprietary boron-10 targeted drugs with the Alphabeam™ accelerator-based neutron beam system for biologically targeted radiation therapy of cancer. The Alphabeam system is a compact tandem accelerator-based neutron source designed for hospital installation, while the boron-10 drug pipeline includes BPA, TC220, TC221, TC440, BTS, Antibody Boron Conjugates, and biodegradable nanoparticles targeting recurrent, invasive, and treatment-resistant cancers.

Product overview

TAE Life Sciences is developing a comprehensive BNCT (Boron Neutron Capture Therapy) platform consisting of the Alphabeam™ Neutron System (an accelerator-based neutron source for hospital deployment) combined with a pipeline of proprietary boron-10 drugs (including BPA, TC220, TC221, TC440, BTS, Antibody Boron Conjugates, and biodegradable nanoparticles). The Alphabeam system generates low-energy neutrons that interact with boron-10 drugs accumulated in tumor cells, causing selective destruction of cancer cells while sparing healthy tissue. The company is the only organization developing both the neutron beam system and targeted boron drugs internally for BNCT.

Differentiator

Problem solved

Functional benefit

Brands

  • Alphabeam: The Alphabeam™ Neutron System is the company's accelerator-based neutron source designed for hospital installation, producing low-energy neutrons for BNCT treatment.
  • BTS (Boronotyrosine)
  • TC220
  • TC440
  • ABCs (Antibody Boron Conjugates)

Products and services

  • Alphabeam Neutron System A compact tandem accelerator-based neutron source designed for hospital installation that generates low-energy neutrons for BNCT cancer treatment. Features 2.5 MeV proton energy, 10+ mA beam current capacity, lithium neutron target technology, negative ion electrostatic accelerator with no moving parts, and the smallest facility footprint for in-hospital use. Targets hospitals and cancer treatment centers implementing biologically targeted radiation therapy for recurrent, invasive, and treatment-resistant cancers.
  • BPA (Boronophenylalanine) / Steboronine The first clinically approved boron-10 drug for BNCT, approved in Japan for head and neck cancer treatment. TAE Life Sciences is the exclusive commercial partner for Stella Pharma's BPA in the USA and Europe, working toward FDA and European approval under the product name Steboronine.
  • TC220 (Boronated Amino Acid Analog) A novel boronated amino acid analog drug for BNCT targeting tumors expressing LAT-1, demonstrating superior boron delivery compared to BPA in preclinical studies. In preclinical development for GBM, breast, head and neck, and melanoma cancers. Manufactured by Biddle Sawyer with Kinentia Biosciences as exclusive manufacturer for US market.
  • TC221 A next-generation boron drug candidate in preclinical development targeting lung, colon, and skin cancers.
  • TC440 Boronated Dipeptide A boronated dipeptide compound demonstrating 2-3x higher boron delivery than BPA in xenograft models with 41% complete tumor remission versus 20% for BPA at same dose. Formulated in aqueous solutions at concentrations greater than 150mg/ml, with dual uptake via PEPT1 and LAT1 transporters.
  • BTS (Boronotyrosine) / BTS(OMe) A patented borylated amino acid composition (US Patent No. 11,884,688 B2) comprising tyrosine derivatives BTS and BTS(OMe) for use in BNCT. Demonstrated 2-4x higher cellular uptake compared to BPA, 60% boron retention after 18 hours versus less than 20% for BPA, and improved tumor-to-blood ratio of 28:1 versus 6:1 for BPA.
  • Antibody Boron Conjugates (ABCs) Next-generation boron drugs leveraging antibody-drug conjugate technology to improve tumor targeting and increase boron loading per cell. TAE Life Sciences has developed boron-enriched linkers (BELs) capable of carrying up to 400 boron atoms per antibody.
  • Biodegradable Nanoparticles (BPMOs) Biodegradable mesoporous organosilica nanoparticles (BPMOs) developed in collaboration with Kyoto University for enhanced boron-10 delivery using the EPR effect for tumor targeting.

Quantifiable outcome

  • 3x more destructive to cancer cells than standard radiotherapy
  • +7 more outcomes

Companies that use TAE Life Sciences

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

TAE Life Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature6 records

TAE Life Sciences partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core and minor.

  • CNAO (National Center for Oncological Hadrontherapy)coreStrategic or Co-development Partner · 20 June 2026Research and clinical collaboration for implementation of BNCT system in Italy. CNAO is one of few facilities worldwide capable of delivering hadrontherapy using both protons and carbon ions, having treated over 6,000 patients. Expanding with BNCT including helium therapy, upright positioning systems, and BNCT system from TAE Life Science.
  • Bozlu HoldingcoreChannel Partner/ Reseller/ Distributor · 5 February 2026Exclusive distribution agreement for Turkiye, Eastern Europe, and Central Asia. Bozlu Holding is a diversified holding company headquartered in Istanbul with over 35 years of healthcare services expertise. Responsible for marketing, promoting, distributing, and selling the Alphabeam BNCT system and supporting deployment at initial clinical sites for regulatory approval in the region.
  • Institut du Cancer de Montpellier (ICM)minorStrategic or Co-development Partner · 18 December 2025Launch of AMBER Project to establish BNCT in France. Project aims to deploy TAE Life Sciences' Alphabeam BNCT system contingent on securing 45 million euros in funding to build dedicated facility.
  • University of Wisconsin-MadisoncoreStrategic or Co-development Partner · 25 September 2025MOU signed to be the first US site to install the Alphabeam BNCT system and execute first US clinical trials. Focus on head and neck and brain cancers.
  • Transmedic GroupcoreChannel Partner/ Reseller/ Distributor · 23 April 2025Strategic partnership to bring BNCT to Southeast Asia. Transmedic, a leading medical technology distributor headquartered in Singapore with over 40 years of local expertise, represents TAE Life Sciences in key Southeast Asian markets including Singapore, Malaysia, Hong Kong, and Thailand. Provides clinical, operational, and regulatory support to bring Alphabeam BNCT to regional hospitals.
  • alphaXRTcoreChannel Partner/ Reseller/ Distributor · 1 April 2025Distribution agreement for Australia and New Zealand. alphaXRT, the leading independent supplier of radiation oncology equipment in Australia and New Zealand since 1990, will distribute Alphabeam BNCT system and novel boron drugs while also providing associated services. alphaXRT holds the regulatory certificate for BNCT in the region.
  • Kyoto UniversitycoreStrategic or Co-development Partner · 15 November 2024Preclinical research collaboration demonstrating breakthrough results in BNCT. Utilizing TAE Life Sciences' novel boron-10 drugs and Kyoto University Research Reactor (KURR) neutron source, research published in Journal of Medicinal Chemistry demonstrated abscopal effects and immune memory responses in BNCT treatment.
  • Stella PharmacoreStrategic or Co-development Partner · 13 November 2024Strategic collaboration for BPA development, commercialization, and expansion in USA and European markets. Stella Pharma's BPA (Steboronine) is the world's first and only clinically approved boron drug for BNCT. Japan approved BNCT with Stella Pharma's BPA for head and neck cancers. TAE Life Sciences serves as exclusive commercial partner for Stella Pharma's BPA in USA and Europe. Clinical trials anticipated to begin in 2026.
  • Radiosurgery GlobalminorChannel Partner/ Reseller/ Distributor · 5 June 2024New distribution partner for India. RSG provides comprehensive support through network of consultants and advisors specializing in sales channels, project management, construction, digital and print marketing, investment advisory, engineering, service, and financing.
  • Neuboron Medical Group / Neuboron Medtech Ltd.coreStrategic or Co-development Partner · 4 April 2024Partnership for Chinese market where TAE Life Sciences' neutron beam system is a key component of Neuboron's NeuPex AB-BNCT System. System received performance acceptance and passed Class III registration inspection enabling human BNCT clinical trials to begin in China. First US company to achieve such recognition. Clinical trials commenced at Xiamen Humanity Hospital.
  • Franciszek Lukasczyk Oncology Center (FLOC)minorStrategic or Co-development Partner · 28 June 2023Partnership with leading cancer center in Poland for new state-of-the-art BNCT facility. Construction projected to complete by 2025 with first clinical trials scheduled to commence in spring 2026.
  • Biddle SawyercoreImplementation/ SI/ Consulting Partner · 15 April 2023Exclusive agreement with Biddle Sawyer as supplier of TC220, a novel boronated amino acid analog drug for BNCT. Biddle Sawyer enlisted Kinentia Biosciences as exclusive manufacturer of TC220 for US market to refine and streamline drug's manufacturing process in GMP facility.
  • Xiamen Humanity HospitalcoreStrategic or Co-development Partner · 15 February 2023First accelerator-based BNCT clinical research center in China using TAE Life Sciences' Neutron Beam System as part of Neuboron Medical Group's NeuPex System. First cancer patient treatments completed.
  • Aivita BiomedicalminorStrategic or Co-development Partner · 30 January 2023Strategic partnership to address unmet need in glioblastoma treatment, combining Aivita's stem cell applications with TAE Life Sciences' BNCT technology.
  • HDX CorporationminorChannel Partner/ Reseller/ Distributor · 30 December 2022Partnership to bring TAE Life Sciences' targeted radiation therapy to South Korea for treatment of difficult-to-treat cancers such as brain, head and neck cancers and melanoma.
  • CNAO (National Center of Oncological Hadrontherapy)coreStrategic or Co-development Partner · 27 October 2020Agreement to provide Alphabeam Neutron System for treatment of invasive, recurrent and difficult to treat cancers in Italy.

Scale indicators6 records

Recent moves7 records

Expansion highlights8 records

TAE Life Sciences competitors and assessment

Company assessment

Direct peers

  • Neuboron Medical Group: China-based developer of the NeuPex AB-BNCT system that integrates TAE Life Sciences' neutron beam with Neuboron technology. Direct competitor in BNCT platform delivery and the closest peer in accelerator-based BNCT system development.
  • Stella Pharma: Japanese pharmaceutical company that developed Steboronine (BPA), the world's first clinically approved boron drug for BNCT, approved in Japan for head and neck cancer. Direct peer in BNCT drug development and TAE's exclusive US/EU commercial partner.
  • Sumitomo Heavy Industries: Japanese industrial conglomerate that developed reactor-based BNCT systems (used at Kyoto University and other Japanese centers). Direct competitor in BNCT hardware, particularly for hospital and research installations in Asia.

Broad incumbents

  • Accuray: US-based radiation oncology systems company (CyberKnife, TomoTherapy) where TAE's CEO Robert Hill was previously SVP. Competes for the same hospital radiation oncology capital budgets but with established photon-based alternatives rather than BNCT.
  • RaySearch Laboratories: Swedish developer of RayStation treatment planning software, which is integrated with TAE's Alphabeam system. Competes in radiation oncology treatment planning broadly and is a strategic partner/dependency for TAE's BNCT workflow.
  • Varian Medical Systems (Siemens Healthineers): Global leader in radiation oncology hardware and software (TrueBeam, Ethos), now part of Siemens Healthineers. Competes for hospital oncology capex with mature conventional and adaptive radiotherapy platforms that BNCT must displace.
  • Elekta: Swedish-Swiss manufacturer of linear accelerators and radiation therapy solutions including the Elekta Unity MR-LinAc. Competes in the same hospital radiation oncology purchasing decisions where TAE's BNCT system would be evaluated.
  • Ion Beam Applications (IBA): Belgian leader in proton therapy systems (ProteusONE, ProteusPLUS) and a major competitor for the particle therapy capital budgets that BNCT systems must compete against in leading cancer centers.
  • Hitachi (Particle Therapy): Japanese conglomerate with significant proton and particle therapy system business globally. Competes for hospital particle therapy installations and represents an alternative path for hospitals exploring advanced radiotherapy.

Emerging players

  • Mevion Medical Systems: US-based developer of compact proton therapy systems (MEVION S250i). Competes with TAE in the niche of smaller-form-factor hospital-installable particle therapy, pursuing similar miniaturization thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

TAE Life Sciences social profiles

Digital presence

TAE Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TAE Life Sciences leadership team

Management profile

Number of profiles

Profiles8 records

TAE Life Sciences funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TAE Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TAE Life Sciences

What does TAE Life Sciences do?

TAE Life Sciences develops Boron Neutron Capture Therapy (BNCT) technology, combining proprietary boron-10 targeted drugs with the Alphabeam™ accelerator-based neutron beam system for biologically targeted radiation therapy of cancer. The Alphabeam system is a compact tandem accelerator-based neutron source designed for hospital installation, while the boron-10 drug pipeline includes BPA, TC220, TC221, TC440, BTS, Antibody Boron Conjugates, and biodegradable nanoparticles targeting recurrent, invasive, and treatment-resistant cancers.

Is TAE Life Sciences a public or private company?

TAE Life Sciences is a private company. It is classified as corporate owned and is currently operating.

When was TAE Life Sciences founded?

TAE Life Sciences was founded in 2017. It employs 51 to 100 people.

Where is TAE Life Sciences based?

TAE Life Sciences is headquartered in Irvine, United States, in the North America region.

How does TAE Life Sciences make money?

Four revenue lines are on record. Alphabeam BNCT System Sales are the primary driver. The others are boron-10 Drug Products, distribution Partnerships and BPA (Steboronine) Commercialization.

Who are TAE Life Sciences's main competitors?

Direct peers on record are Neuboron Medical Group, Stella Pharma and Sumitomo Heavy Industries. Broad incumbents are Accuray, RaySearch Laboratories, Varian Medical Systems (Siemens Healthineers), Elekta, Ion Beam Applications (IBA) and Hitachi (Particle Therapy). Mevion Medical Systems is listed as an emerging player.

Does TAE Life Sciences have an API?

No public API is recorded for TAE Life Sciences.

What industry is TAE Life Sciences in?

TAE Life Sciences's product category is Radiation Oncology Systems. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 334517 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
OcbjTAE Life Sciences Signs Taiwan Manufacturing DealTAE Life Sciences signed a contract manufacturing agreement with Foxsemicon Integrated Technology in Taiwan to develop targeted radiation treatments. FITI will manufacture and test components, while TAE performs final assembly and integration. The deal strengthens TAE's manufacturing supply chain for its Alphabeam system.The future of tradingTAE Life Sciences Announces Manufacturing Partnership With Foxsemicon Integrated TechnologyTAE Life Sciences announced a contract manufacturing partnership with Foxsemicon Integrated Technology for its Alphabeam BNCT system. The partnership is for manufacturing the system, with no further details provided.YahooTAE Life Sciences Announces Contract Manufacturing Partnership with Foxsemicon Integrated Technology (FITI) for Alphabeam™ BNCT SystemTAE Life Sciences announced a contract manufacturing agreement with Foxsemicon Integrated Technology (FITI) for its Alphabeam BNCT systems. FITI will handle component fabrication, assembly, and testing, while TAE retains final system assembly and installation. The partnership aims to scale production while maintaining quality control.Business Wire BlogTAE Life Sciences Announces Contract Manufacturing Partnership with Foxsemicon Integrated Technology (FITI) for Alphabeam™ BNCT SystemTAE Life Sciences announced a contract manufacturing agreement with Foxsemicon Integrated Technology (FITI) for its Alphabeam BNCT system. FITI will handle component fabrication, assembly, and testing, while TAE retains final system assembly and installation. The partnership aims to scale production without compromising quality.The Daily CardinalNeutron Capture Therapy makes UW-Madison ‘hotbed’ for cancer innovationThe University of Wisconsin-Madison partnered with TAE Life Sciences to launch the first clinical site for Neutron Capture Therapy (NCT) in the United States, aiming to establish a national hub for cancer innovation. This targeted treatment utilizes a particle accelerator and boron-10 drugs to destroy tumor cells with minimal damage to healthy tissue, offering a faster and less invasive alternative to traditional therapies. The initiative is currently awaiting necessary funding, construction completion, and FDA approval to proceed with clinical trials.PR Newswire APACPope Leo XIV embraces paediatric patients at CNAO in PaviaPope Leo XIV began his pastoral visit to Pavia, Italy, at the National Center for Oncological Hadrontherapy (CNAO), where he met with young paediatric patients and their families, symbolizing the intersection of advanced medical science and human compassion. CNAO is one of the few facilities worldwide capable of delivering hadrontherapy using both protons and carbon ions, having treated over 6,000 patients including approximately 300 children. The center is expanding its capabilities with new technologies including helium therapy, upright positioning systems from Leo Cancer Care, a Hitachi proton accelerator, and a BNCT system equipped with an electrostatic accelerator from TAE Life Science.Business Wire BlogTAE Life Sciences Announces Breakthrough BNCT Research Demonstrating Durable Tumor Control and Systemic Immune EffectsTAE Life Sciences announced publication of new research in ACS Pharmacology & Translational Science demonstrating that its next-generation boron delivery platform for Boron Neutron Capture Therapy (BNCT) may enable both enhanced tumor control and systemic immune activation. The study showed their proprietary BPA-based dipeptides achieved 12- to 77-fold higher solubility than standard BPA, resulting in complete and durable tumor regressions including 100% complete response rates in a human head and neck cancer xenograft model. Beyond local tumor control, the research demonstrated that BNCT can activate a systemic anti-tumor immune response and function as an in situ tumor vaccine, supporting potential combination strategies with immune checkpoint inhibitors and other systemic treatments.BioSpaceTAE Life Sciences Announces Breakthrough BNCT Research Demonstrating Durable Tumor Control and Systemic Immune EffectsTAE Life Sciences announced the publication of new research in ACS Pharmacology & Translational Science demonstrating that its next-generation boron delivery platform for Boron Neutron Capture Therapy achieved 12- to 77-fold higher solubility than standard BPA, resulting in 100% complete response rates in preclinical head and neck cancer models. The study also showed that BNCT activated a systemic anti-tumor immune response in mouse models, including tumor rejection upon rechallenge and suppression of untreated tumors at distant sites. The findings position BNCT as a dual-mechanism modality with potential for combination strategies with immune checkpoint inhibitors and other systemic treatments for hard-to-treat cancers.BioSpaceInstitut du Cancer de Montpellier and TAE Life Sciences Launch AMBER Project to Bring BNCT to FranceThe Institut du Cancer de Montpellier (ICM) and TAE Life Sciences signed an agreement to launch the AMBER Project, establishing Boron Neutron Capture Therapy (BNCT) in France using TAE Life Sciences' Alphabeam BNCT system. Subject to securing €45 million in funding by the first half of the year, ICM will construct a dedicated BNCT facility on its campus to treat poor-prognosis cancers including high-grade brain tumors and pancreatic cancer. The project aims to position Montpellier among Europe's leaders in oncology innovation and create new therapeutic pathways for cancers currently considered incurable.WiscUW–Madison to lead nation in boron neutron capture therapy for cancerThe University of Wisconsin–Madison and TAE Life Sciences signed an MOU to launch the first accelerator-based boron neutron capture therapy center in the United States. The collaboration will develop Alphabeam and novel boron-10 drugs for brain and head and neck cancers, with UW-Madison installing the system.